Contrasting Gain Therapeutics (NASDAQ:GANX) and Cytokinetics (NASDAQ:CYTK)

Gain Therapeutics (NASDAQ:GANX) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Risk and Volatility

Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Valuation and Earnings

This table compares Gain Therapeutics and Cytokinetics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50,000.00	1,152.10	-$20.16 million	($0.50)	-2.64
Cytokinetics	$67.67 million	116.64	-$784.96 million	($7.22)	-8.79

Gain Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Gain Therapeutics and Cytokinetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1	0	4	0	2.60
Cytokinetics	1	1	18	0	2.85

Gain Therapeutics presently has a consensus price target of $7.67, suggesting a potential upside of 480.81%. Cytokinetics has a consensus price target of $105.44, suggesting a potential upside of 66.24%. Given Gain Therapeutics’ higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Cytokinetics.

Institutional & Insider Ownership

12.0% of Gain Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gain Therapeutics and Cytokinetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Cytokinetics	-1,321.12%	N/A	-51.01%

Summary

Gain Therapeutics beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.